Global

Kamal Biswas outlines some techniques for the successful design and implementation of an IT shared services model in pharma.

As Europe sets the pace in slashing drug prices to meet austerity goals industry is seeking fresh ways to control the fallout. Will more dialogue be enough?

Richard Watts and Chris Hart highlight some of the issues companies need to tackle to speed up their drug development process.

As they build market share, companies need a plan to limit exposure to steep fines and executive prosecutions.

June 29, 2010.

As pharma companies protest decisions to cut drug prices in Greece, Spain and Germany, the question of fair play is brought in sharp focus. But, says Jacky Law, even-handedness in drug pricing works both ways.

June 23, 2010.

June 14, 2010.

June 14, 2010.

The broadening of the EU debate on counterfeit medicines may actually have some negative effects on Big Pharma, argues Reflector.

Tell us and win an iPod Touch!

June 4, 2010.

It is now the job of the pharma marketer to get people talking and to listen to what they are saying. Jody Ball offers advice on making that transition.

May 24, 2010.

May 24, 2010.

May 7, 2010.

May 7, 2010.

The three-way race for control of Parliament leaves the future of the British pharmaceutical industry in the balance.

An exclusive report for Pharm Exec Europe by IMS Health.

April 29, 2010.

April 21, 2010.

April 22, 2010.

April 21, 2010.

April 13, 2010.

In 1995, pharmaceutical regulation in Europe underwent a dramatic change with the emergence of the European Medicines Agency. The agency's 15-year history has been eventful, with it having to adapt to a changing regulatory landscape and new expectations from those relying on it for guidance.

March 25, 2010.

The spiralling nature of disclosure in the US provides a cautionary tale for European pharma executives. Jacky Law reports.

Harold Hambrose explains why applying user-centric design to healthcare business systems can save money and lives.

March 24, 2010.

Proving that one good turn deserves another, Pfizer and GlaxoSmithKline announced that they would provide millions of doses of pneumonia vaccines to some of the world's most impoverished countries at massive discounts.